

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

Cannabidiol for adjuvant treatment of seizures associated with Lennox-Gastaut syndrome

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Comments were received at consultation which stated that there was often difficulty in accessing treatment as an adult, particularly where drugs were not licensed for adults – despite there being no difference in the condition.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The appraisal for Lennox-Gastaut syndrome should consider the management of patients as they transition to adulthood.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders were identified.

Approved by Associate Director (name): Melinda Goodall

Date: 26/10/2018